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Abstract 
The clinical benefit of monotherapy involving immune checkpoint inhibitors (ICIs) such as 
anti-programmed death-1 antibody (PD-1 Ab) is limited to small populations. We previously 
developed a telomerase-specific oncolytic adenovirus, Telomelysin (OBP-301), the safety of 
which was confirmed in a phase I clinical study. Here, we examined the potential of OBP-
502, an OBP-301 variant, as an agent for inducing immunogenic cell death (ICD) and 
synergistically enhancing the efficacy of OBP-502 with PD-1 Ab using CT26 murine colon 
cancer and PAN02 murine pancreatic cancer cell lines. OBP-502 induced the release of ICD 
molecules such as ATP and HMGB1 from CT26 and PAN02 cells, leading to recruitment of 
CD8-positive lymphocytes and inhibition of Foxp3-positive lymphocyte infiltration into 
tumors. Combination therapy involving OBP-502 intratumoral administration and PD-1 Ab 
systemic administration significantly suppressed the growth of not only OBP-502-treated 
tumors but also tumors not treated with OBP-502 (so-called abscopal effect) in CT26 and 
PAN02 bilateral subcutaneous tumor models, in which active recruitment of CD8-positve 
lymphocytes was observed even in tumors not treated with OBP-502. This combined efficacy 
was similar to that observed in a CT26 rectal orthotopic tumor model involving liver 
metastases. In conclusion, telomerase-specific oncolytic adenoviruses are promising 
candidates for combined therapies with ICIs. 
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Introduction 
Cancer immunotherapy, a strategy that harnesses the immune system to combat tumors, has 
recently triggered a paradigm shift in the standard treatment of various cancers 1, 2. In 
particular, immune checkpoint inhibitors (ICIs) such as blocking antibodies to cytotoxic T 
lymphocyte antigen 4 (CTLA-4), programmed death-1 (PD-1), and PD-1 ligand-1 (PD-L1) 
have dramatically improved clinical outcomes for patients with malignant tumors such as 
melanoma, non-small-cell lung cancer, Hodgkin's lymphoma, and gastric cancer 3-6. 
However, the clinical benefit of ICI monotherapy is limited to small populations exhibiting 
high expression of PD-L1, high numbers of tumor-infiltrating lymphocytes (TILs), and a high 
mutation burden 5, 7, 8. Therefore, a novel strategy involving combination therapy with various 
therapeutic drugs that enhance tumor immunogenicity is needed to further improve clinical 
outcomes 9. 
Immunogenic cell death (ICD) is a mechanism of cell death that leads to the induction 
of an effective antitumor immune response via the activation of dendritic cells (DCs) and T 
lymphocytes, unlike normal types of cell death such as apoptosis and necrosis. ICD is 
characterized by secretion of damage-associated molecular patterns (DAMPs) such as high-
mobility group box protein 1 (HMGB1) and adenosine triphosphate (ATP) 10, 11. Agents that 
induce ICD have been recognized as ideal partners for combination therapies with ICIs that 
could clinically benefit a larger population of cancer patients. Oncolytic viruses are 
considered such an agent, along with various chemotherapeutics such as oxaliplatin and 
cyclophosphamide, in addition to radiation 12-16. 
We previously established a telomerase-specific oncolytic adenovirus (OBP-301, 
Telomelysin) in which the human telomerase reverse transcriptase (hTERT) promoter 
element drives the expression of the viral E1A and E1B genes 17. This gene modification 
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enables OBP-301 to replicate selectively in tumor cells and induce tumor-specific oncolytic 
cell death. Moreover, following induction of oncolytic cell death, progeny viruses are capable 
of spreading to surrounding tumor cells to cause continued oncolytic cell death. An FDA-
approved phase I clinical study confirmed the safety and biological activity of intratumoral 
administration of OBP-301 in patients with advanced solid tumors in the US 18. Based on its 
safety profile and promising preclinical data regarding combination therapy with ionizing 
radiation, a phase I/II clinical trial is currently ongoing in Japan to evaluate the safety and 
efficacy of the combination for treating esophageal cancer (UMIN000010158) 19. 
In the present study, we first examined the potential of our telomerase-specific 
oncolytic adenovirus as an ICD-inducing drug by assessing the secretion of ICD markers 
such as HMGB1 and ATP in vitro and recruitment of CD8-positive TILs on gastrointestinal 
tumors in vivo. We then examined the efficacy of combination therapy involving our 
oncolytic adenovirus and anti-PD-1 antibody using in vivo subcutaneous and orthotopic 
mouse models, focusing on abscopal effects mediated by the oncolytic adenoviruses via 
activation of the host immune system. Our findings demonstrate the promise of our 
telomerase-specific oncolytic adenovirus therapy, particularly in combination with an ICI. 
Moreover, these findings should facilitate the development of a novel oncolytic virus 




Cytotoxic activity of OBP-502 against murine gastrointestinal cancer cell lines 
OBP-502, a variant of OBP-301, was employed in this study. The difference between OBP-
301 and OBP-502 is that OBP-502 has the gene cassette expressing the RGD peptide in the 
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E3 region (Figure S1A). The RGD peptide facilitates OBP-502 infection of murine tumor 
cells via interaction with the integrin αvβ5 expressed on tumor cells, as OBP-301 infection of 
murine cells such as CT26 and PAN02, which do not express the Coxsackie virus and 
adenovirus receptor (CAR) (Figure S2), is inefficient. 
OBP-502 killed CT26 and PAN02 cells in a dose-dependent and time-dependent 
manner (Figure 1A and Figure S1B), and this cytotoxicity of OBP-502 was higher than OBP-
301, especially at high doses, whereas no significant difference was observed between 
OBP301 and OBP-502 on human cancer cells such as TE4, GCIY, MIA PaCa-2, and 
HCT116 (Figure S1C). This cytotoxicity was associated with induction of apoptosis and 
autophagy following effective infection of murine tumor cells, which was shown by 
induction of E1A, upregulation of cleaved PARP, and downregulation of p62 on Western blot 
analysis (Figure 1B). The cytotoxic mechanism of OBP-502 was considered similar to that of 
OBP-301, an original oncolytic adenovirus 20. Interestingly, treatment with high doses of 
OBP-502 upregulated PD-L1 expression by CT26 and PAN02 cells (Figure 1B), particularly 
on the cell surface (Figure 1C). 
 
Active release of immunogenic molecules and chemokines by OBP-502 in vitro 
OBP-502 significantly increased the release of ATP and HMGB1, which are known to be 
immunogenic molecules, by CT26 and PAN02 cells in vitro 24 hours after treatment (Figure 
2A and 2B) but did not affect the expression of CRT, another immunogenic molecule, in 
either cell line (Figure S3A). Intracellular HMGB1 levels also increased with OBP-502 
treatment (Figure S3B and Figure S3C). OBP-502 decreased β-catenin expression in CT26 
and PAN02 cells (Figure S3D), which is reportedly associated with immune exclusion in the 
tumor microenvironment mediated by the Wnt/β-catenin pathway 21. Multi-cytokine and 
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chemokine assays showed that at 24 hours after treatment, OBP-502 markedly induced the 
release of several chemokines by CT26 cells, such as CCL5/RANTES and CXCL10/IP-10, 
which are known to play an important role in recruiting TILs 22, 23 (Figure 2C). Focusing on 
CCL5/RANTES based on multi-cytokine and chemokine assay results, OBP-502 
significantly increased CCL5/RANTES release by CT26 and PAN02 cells in a dose-
dependent manner (Figure 2D). These results suggested that OBP-502 has the potential to 
induce ICD via the active release of immunogenic molecules and chemokines, leading to 
activation of the host immune response against tumors. 
 
Recruitment of CD8-positive lymphocytes to tumors and development of acquired 
antitumor immunity mediated by OBP-502  
Immunohistochemical staining of CD8, CD11c, CD4, and Foxp3 on CT26 and PAN02 
subcutaneous tumors indicated that OBP-502 treatment significantly increased the number of 
CD8-positive cells in CT26 and PAN02 tumors compared to PBS treatment, whereas OBP-
502 treatment significantly increased the number of CD11c-positive cells in PAN02 tumors, 
but not CT26 tumors (Figure 3A-3C). OBP-502 treatment resulted in a significant decrease in 
the number of Foxp3-positive cells in CT26 tumors but not PAN02 tumors, whereas no 
significant change was observed in the number of CD4-positive cells in either tumor type. 
Recruitment of CD8-positive cells and rejection of Foxp3-positive cells began to be observed 
3 days after a single treatment with OBP-502, whereas no change in CD4-positive cells was 
observed (Figure S4). In CTL assay, CD8-positive lymphocytes (Effector) collected from the 
spleen of mice treated with OBP-502 showed significantly strong cytotoxicity against 
Colon26-GFP cells (Target) at an Effector:Target ratio of 20:1 compared to PBS (Figure 3D 
and 3E). 
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In the vaccination study, compared with PBS-treated mice, tumor growth was 
significantly suppressed after inoculation of CT26 or PAN02 cells in mice vaccinated with 
OBP-502–treated cells (Figure 3F and 3G), and vaccination with OBP-502-treated cells 
actually increased the number of CD8-positive TILs in PAN02 tumors (Figure 3H and 3I). 
These results suggested that OBP-502 strongly activates antitumor immunity by recruiting 
CD8-positive lymphocytes to tumor tissues, and this effect was established as acquired 
antitumor immunity in the treated mice. 
 
Antitumor effects of combination therapy in a subcutaneous tumor model 
The antitumor effects of combination therapy involving OBP-502 and PD-1 Ab were 
evaluated using CT26 and PAN02 subcutaneous tumor models. PD-1 Ab was administered 
systemically 3 days after OBP-502 intratumoral injection, and this combination treatment was 
repeated 3 times each week (Figure 4A). The combination therapy significantly suppressed 
the growth of CT26 tumors compared to PBS and PD-1 Ab monotherapy, and surprisingly, 4 
of 12 mice (33%) given the combination therapy became tumor free, whereas monotherapy 
with either OBP-502 or PD-1 Ab eradicated the tumors in 1 and 0 of the 12 mice, 
respectively (Figure 4B). When the tumor-free mice cured by combination therapy were re-
challenged with CT26 inoculation, 2 of the 4 mice (50%) remained tumor free (Figure 4C). 
The combination therapy also significantly suppressed the growth of PAN02 tumors, which 
are reportedly ICI-resistant 24, and 1 of 7 mice (14%) became tumor free, but PD-1 Ab alone 
had no effect on PAN02 tumors (Figure 4D). Immunohistochemical staining showed that 
combination therapy led to recruitment of more CD8-positive TILs compared with controls at 
28 days after initiation of treatment (Figure 4E). Although PD-1 Ab treatment or combination 
therapy with the antibody and another therapeutic agent are reportedly associated with severe 
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adverse effects in several major organs, such as the lungs, pancreas, and thyroid gland 25, no 
signs of severe toxicity were observed in any major organs harvested 28 days after 
combination therapy against CT26 subcutaneous tumors (Figure S5). These results 
demonstrated the possibility that OBP-502 and PD-1 Ab combination therapy could become 
an attractive treatment option for gastrointestinal tumors due to its profound beneficial effects 
and favorable safety profile. 
 
Abscopal effects of combination therapy in a bilateral subcutaneous tumor model 
The abscopal effect is an interesting phenomenon in which tumor shrinkage at metastatic 
sites can be achieved following application of local therapy, such as radiotherapy, and the 
immune system is considered to play a key role in this process. When we first assessed 
whether OBP-502 monotherapy induced an abscopal effect in a CT26 bilateral subcutaneous 
tumor model (Figure 5A), we found that OBP-502 intratumoral injection exhibited significant 
therapeutic effects not only at the treated site, but also at untreated sites, when compared to 
PBS (Figure 5B), and these effects involved efficient recruitment of CD8-positive cells 
(Figure S6A). However, the abscopal effect was diminished when the same experiment was 
performed using T cell-deficient BALB/c nude mice (Figure 5C; Figure S6B).  
When abscopal effects associated with combination therapy with PD-1 Ab were 
assessed using the same CT26 bilateral subcutaneous tumor model, combination therapy 
exhibited significant therapeutic effects at both the treated and untreated site compared to 
control therapies (Figure 5D). Surprisingly, this combination therapy eradicated tumors at the 
treated site in 67% of mice (4/6) and at the untreated site in 33% of mice (2/6), whereas 
monotherapy with either agent eradicated no tumors at the treated or untreated sites in any of 
the mice. Combination therapy with OBP-502 strongly recruited CD8-positive TILs to both 
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the treated and untreated sites compared to control therapies (Figure 5E and 5F), and 
combination therapy significantly decreased the number of Foxp3-positive TILs at the treated 
site, but not at the untreated site (Figure S7). Furthermore, when mice rendered tumor free 
(n=4) by combination therapy against CT26 tumors were re-challenged with CT26 
inoculation, all 4 mice remained tumor free (Figure 5G). These results suggested that OBP-
502 intratumoral injection has the potential to produce abscopal effects via the activation of 
systemic antitumor immunity and that these effects are enhanced by combination therapy 
with PD-1 Ab. 
 
Antitumor effects of combination therapy in a CT26 orthotopic rectal tumor model with 
liver metastases 
Finally, in order to evaluate the therapeutic effects of combination therapy in a model more 
closely related to clinical practice than a bilateral subcutaneous tumor model, we developed a 
CT26 orthotopic rectal tumor model with liver metastases and treated the mice using the 
same protocol (Figure 6A). Kaplan-Meier analysis showed that combination therapy 
significantly prolonged survival (Figure 6B), and IVIS imaging demonstrated that the 
combination therapy actually suppressed the growth of liver metastases as well as rectal 
tumors (Figure 6C-6E). The effectiveness of combination therapy against liver metastases 




Combined immunotherapy has become a hot topic in the field of cancer immunotherapy as 
clinicians have realized that the clinical benefits of ICI monotherapy are limited to a small 
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proportion of patients. Worldwide, over 500 clinical trials evaluating combination therapy 
involving anti-PD-1/PD-L1 Ab with other therapeutic agents are currently ongoing, and the 
most common combination involves anti-CTLA-4 agents, followed by chemotherapy and 
radiotherapy 26. The combination of nivolumab and ipilimumab has been proven effective for 
patients with advanced melanoma or renal cell carcinoma in phase III clinical trials 27, 28, and 
the combination of pembrolizumab and chemotherapy has also shown significant survival 
prolongation in patients with advanced non-small-cell lung cancer 29. Another intriguing 
strategy is combination with oncolytic viruses, for which several clinical trials are currently 
ongoing 30. Talimogene laherparepvec (i.e., T-VEC), the first oncolytic herpes simplex virus, 
exhibited therapeutic benefits against advanced melanoma as a monotherapy in a phase III 
clinical trial 31 and recently demonstrated promising efficacy and acceptable safety in 
combination with pembrolizumab for patients with advanced melanoma in a phase Ib clinical 
trial 32. Coxsackie virus A21 (CVA21), an unmodified common-cold RNA virus, also seems 
to have produced durable responses with minimal toxicity in combination with ipilimumab 
for patients with advanced melanoma in a phase Ib clinical trial 33. 
TIL-rich tumors respond to ICIs 34. From this viewpoint, preferred combination 
partners with ICIs include agents that are capable of inducing ICD. Along with some 
chemotherapeutics such as oxaliplatin and cyclophosphamide, oncolytic viruses are potent 
ICD-inducing agents 14, 15. We previously reported that OBP-301, a telomerase-specific 
oncolytic adenovirus, releases a danger signal (i.e., uric acid) that triggers an immune 
response against human cancer cells 35. In addition, we showed that OBP-502, a variant of 
OBP-301, significantly increased the release of ATP and HMGB1 via the induction of 
autophagic and apoptotic cell death of murine colon cancer and pancreatic cancer cells in this 
study, indicating that OBP-502 is also a potent ICD inducer. Treatment with OBP-502, 
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however, did not increase the expression of CRT, which is recognized as an ICD marker 
along with ATP and HMGB1, although the reasons for this remain unclear. Various 
chemokines are also associated with the recruitment of immune cells 22, 23. An oncolytic 
poxvirus and vaccinia virus expressing CXCL11 reportedly generated a systemic immune 
response and sensitized murine tumors to ICIs 36, 37. We demonstrated in this study that OBP-
502 increases the release of various chemokines, such as CCL5/RANTES and CXCL10/IP-
10, both of which play an important role in recruiting CD8-positive TILs 38, and this is 
consistent with a previous report indicating that adenoviruses originally induce chemokines 
such as CCL5/RANTES and CXCL10/IP-10 following infection of cells 39. Through the 
release of these ICD molecules and chemokines, OBP-502 facilitates the recruitment of CD8-
positive lymphocytes and DCs into CT26 and PAN02 tumor tissues, and this immune 
activation by OBP-502 is long lasting as acquired immunity. OBP-502 This effect is 
particularly important with respect to tumors such as PAN02, so-called “cold” tumors that 
normally have few TILs; therefore, we can say that OBP-502 has the potential to turn 
immunologically “cold” tumors into “hot” tumors. 
The mechanism underlying the abscopal effect remains unknown, even decades after 
this phenomenon was first reported in the 1970s as a rare unpredictable biological behavior 
involving simultaneous regression of distant untreated metastases after local radiotherapy 40. 
Systemic antitumor immune activation after local radiotherapy was recently recognized as a 
primary contributor to the abscopal effect 41, and combination therapies with ICIs such as 
ipilimumab reportedly increase the number of patients that can benefit from abscopal effects 
42, 43. Oncolytic virotherapy, mostly involving intratumoral injection, also reportedly induces 
abscopal effects 44. In this study, we demonstrated that OBP-502 has the potential to induce 
abscopal effects in a bilateral subcutaneous tumor model of CT26 and PAN02 cells. 
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Furthermore, combination therapy employing OBP-502 and PD-1 Ab markedly suppressed 
tumor growth by recruiting CD8-positive lymphocytes, even into tumors not treated with 
OBP-502, and surprisingly, eradicated some of these untreated CT26 or PAN02 tumors, 
while either monotherapy had little effect.  
PD-L1 is generally considered a biomarker of anti-PD-1 therapy 45, and it is 
reportedly upregulated by INF-γ through the Janus kinase–signal transducer and activator of 
transcription pathway 46. As some chemotherapies and radiotherapy reportedly upregulate 
PD-L1 expression on the surface of cancer cells 47, 48, we found that OBP-502 upregulated 
PD-L1 expression both within and on the surface of CT26 and PAN02 cells. Although we did 
not investigate further the detailed mechanism in this study, stimulation of IFN-γ release by 
oncolytic adenoviruses, as we previously reported 35, is presumably associated with this PD-
L1 upregulation, and PD-L1 upregulation by OBP-502 may be the mechanism underlying the 
synergistic effect of combination therapy with PD-1 Ab. We showed that OBP-502 reduced 
β-catenin in CT26 and PAN02 cells in vitro and suppressed recruitment of Foxp3-positive 
cells in CT26 tumor tissues in vivo, which are another interesting aspect of OBP-502, but 
detailed mechanisms for these remain unclear. 
Although the present study has demonstrated the promising antitumor activity of 
OBP-502 via immune activation, there were several discrepancies in this study. For example, 
OBP-502 showed decent cytotoxic effects on CT26 and PAN02 cells at a high dose in vitro 
(Figure 1A), but OBP-502 did not show significant antitumor effects on CT26 tumors in 
similar immune-deficient conditions in vivo using immune-deficient mice, although the 
tendency or an antitumor effect was observed for OBP-502 (Figure 5C). Another discrepancy 
is that combination therapy of OBP-502 and PD-1 Ab did not increase recruitment of CD8-
positive TILs at treated sites in the CT26 bilateral subcutaneous tumor model, while 
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combination therapy significantly increased recruitment of CD8-positive TILs at untreated 
sites (Figure 5F). 
In the present study, we demonstrated that our telomerase-specific oncolytic 
adenovirus can facilitate CTL recruitment into tumor tissues through ICD induction after 
intratumoral administration, leading to abscopal effects via activation of systemic antitumor 
immune responses. Combination therapy with PD-1 Ab created synergistic antitumor effects 
that even led to tumor eradication. These findings support the contention that novel 
therapeutic strategies employing oncolytic virotherapy are ideal partners for ICIs and that this 
combination can yield improved clinical benefits for patients with advanced tumors with 
distant metastases. We recently launched a multicenter, open-label phase I clinical study to 
evaluate the efficacy and safety of OBP-301 in combination with pembrolizumab in patients 
with advanced solid tumors (EPOC1505) (NCT03172819), for which data from the present 
study will serve as proof of concept. We expect that oncolytic virotherapy will be the next 
great breakthrough in cancer therapy, following immunotherapy, and that combination 
therapy with ICIs will be the most promising therapeutic strategy. 
 
Materials and Methods 
Cell lines and cell cultures 
The murine colon cancer cell line CT26 derived from BALB/c mice was purchased from the 
American Type Culture Collection (ATCC, Manassas, VA, USA), and the murine pancreatic 
cancer cell line PAN02 derived from C57BL/6 mice was purchased from the National Cancer 
Institute (Frederick, MD, USA). These cancer cell lines were cultured in RPMI medium 
supplemented with 10% fetal calf serum and 1% penicillin-streptomycin (100 U/ml). Neither 
cell line was cultured for more than 3 months following resuscitation. Cell authentication was 
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not performed by the authors.  
 
Oncolytic adenovirus and ICI 
OBP-502 (Figure S1), a variant of OBP-301, was employed in this study. OBP-502 has a 
mutant fiber containing the RGD peptide to facilitate infection of murine tumor cells via 
interaction with the integrin αvβ5 expressed on tumor cells, as OBP-301 infection of murine 
cells such as CT26 and PAN02, which do not express the CAR (Figure S2), is inefficient. 
Multiplicity of infection (MOI) and plaque-forming units (PFU) were used as virus units in 
vitro and in vivo, respectively. Anti-PD-1 antibody (clone 4H2) (PD-1 Ab) was obtained 
from Ono Pharmaceutical Co., Ltd. 
 
Cell viability assay 
CT26 and PAN02 cells were seeded in 96-well plates (1×103 cells/well) (n=5) and treated 
with OBP-502 at the indicated MOI. Cell viability was determined 3 days after treatment 




Formalin-fixed, paraffin-embedded tissue samples cut at 4 μm were deparaffinized in xylene 
and rehydrated using a graded ethanol series. After blocking endogenous peroxidases by 
incubation with 3% H2O2 for 10 min, the samples were boiled in citrate buffer or EDTA 
buffer for 14 min in a microwave oven for antigen retrieval. The samples were incubated with 
primary antibodies for 1 h at room temperature or overnight at 4°C and then with peroxidase-
linked secondary antibody for 30 min at room temperature. Samples were stained with 3,3-
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diaminobenzidine for signal generation, counterstained with Mayer’s hematoxylin, and then 
dehydrated and mounted onto coverslips. Antibodies to CD8 (eBioscience, San Diego, CA, 
USA), CD11c (Abcam, Cambridge, MA, USA), CD4 (eBioscience), and Foxp3 
(eBioscience) were used. The number of cells expressing CD8, CD11c, CD4, and Foxp3, 
which indicate cytotoxic T lymphocytes (CTLs), DCs, helper T lymphocytes, and regulatory 
T lymphocytes, respectively, was determined from five randomly selected fields. 
 
Flow cytometry 
Cells were incubated with antibody to PD-L1 (Biolegend, San Diego, CA, USA) for 30 min 
on ice and analyzed using a FACS Array (BD Biosciences, San Jose, CA, USA).  
       
ATP and HMGB1 assays 
CT26 and PAN02 cells were treated with OBP-502 (0, 500, and 1000 MOI) for 24 h (n=5), 
after which levels of extracellular ATP and HMGB1 in the supernatants were measured using 
an ENLITEN ATP assay (Promega, Madison, WI, USA) and HMGB1 ELISA Kit II (Shino-
Test, Kanagawa, Japan), respectively, according to the manufacturers’ protocols. 
 
Multi-cytokine and chemokine assays  
CT26 and PAN02 cells were treated with OBP-502 (0, 500, and 1000 MOI) for 24 h (n=5), 
after which various cytokines and chemokines in the supernatants were measured using a 
mouse cytokine array (R&D Systems, Minneapolis, MN, USA) and CCL5/RANTES ELISA 
kit (R&D Systems), respectively, according to the manufacturers’ protocols. 
 
Western blot analysis 
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Proteins extracted from whole-cell lysates were electrophoresed on 10-15% SDS-
polyacrylamide gels and transferred onto Hybond-polyvinylidene difluoride transfer 
membranes (GE Healthcare UK Ltd., UK). The membranes were incubated with primary 
antibodies against adenovirus type 5 E1A (BD Biosciences, Franklin Lakes, NJ, USA), 
poly(ADP ribose) polymerase (PARP) (Cell Signaling Technology), p62 (SQSTM1) 
(Medical & Biological Laboratories [MBL], Nagoya, Japan), PD-L1 (Abcam, Cambridge, 
MA, USA), and β-Actin (Sigma-Aldrich, Saint Louis, MO, USA), followed by peroxidase-
linked secondary antibody. The Amersham ECL chemiluminescence system (GE Healthcare 
UK Ltd.) was used to detect the peroxidase activity of the bound antibody. Equal loading of 
samples was confirmed using β-Actin.  
 
In vivo experiments 
CT26 cells (1×106 cells) were subcutaneously injected into the flanks of 6-week-old female 
BALB/c mice and BALB/c nude mice, and PAN02 cells (1×106 cells) were subcutaneously 
injected into the flanks of 6-week-old female C57BL/6 mice. Treatment was initiated when 
tumors reached a diameter of approximately 5 mm. The perpendicular diameter of each tumor 
was then measured twice per week, and tumor volume was calculated using the following 
formula: tumor volume (mm3) = a×b2×0.5, where a represents the longest diameter, b 
represents the shortest diameter, and 0.5 is a constant used to calculate the volume of an 
ellipsoid. 
To evaluate the effect of OBP-502 on TILs, CT26 and PAN02 subcutaneous tumors 
were treated intratumorally with OBP-502 (1×109 plaque-forming units [PFU]) or PBS 3 
times per week. The mice were sacrificed 7 days after initiation of treatment to investigate the 
effect on TILs. 
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CT26 and PAN02 subcutaneous tumors were treated intratumorally with OBP-502 
injection (1×109 PFU) and intraperitoneal PD-1 Ab injection (1st: 20 mg/kg, 2nd/3rd: 10 
mg/kg) 3 times each week49, and tumor volume was monitored until day 28 to assess the 
therapeutic efficacy of OBP-502 and PD-1 Ab combination therapy. Tumor-free mice cured 
after combination therapy were subcutaneously re-challenged with inoculation of CT26 cells 
(5×105 cells).  
CT26 and PAN02 bilateral subcutaneous tumor models were prepared in BALB/c 
mice or BALB/c nude mice (for CT26) and C57BL/6 mice (for PAN02) to investigate 
abscopal effects of OBP-502 alone or in combination therapy with PD-1 Ab. One side was 
treated with OBP-502 intratumorally 3 times each week, and the other side was left untreated. 
PD-1 Ab was administered intraperitoneally 3 times each week. Tumor volume was 
monitored until day 21-24. 
To establish an orthotopic rectal tumor model with liver metastases, CT26 cells stably 
expressing luciferase (CT26-Luc) were inoculated into the submucosal layer of the rectum 
(1×106 cells) of BALB/c mice, followed by injection of 5×105 cells via the portal vein 2 days 
after rectum inoculation. Mice were treated with OBP-502 intratumorally and PD-1 Ab 
intraperitoneally 3 times each week starting 5 days after portal vein injection. Tumor growth 
was monitored using an IVIS imaging system (Xenogen), and survival was assessed by 
Kaplan-Meier analysis.  
Mice were housed in a specific pathogen-free environment in the Department of 
Animal Resources of Okayama University. All animal experimental protocols were approved 
by the Institutional Animal Care and Use Committee of Okayama University. 
 
CTL assay 
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The GFP-expressing murine colon cancer cell line Colon26-GFP (1×106 cells), kindly 
provided by Dr. Hoffmann of AntiCancer Inc (San Diego, CA), were subcutaneously injected 
into the flanks of 6-week-old female BALB/c mice. Colon26-GFP subcutaneous tumors were 
treated intratumorally with PBS or OBP-502 injection (1×109 PFU) 3 times a week, and the 
mice were sacrificed 7 days after initiation of treatment (n=3). Splenocytes, collected by 
homogenization of the spleen, were treated by RBC lysis buffer (Biolegend) and Debris 
removal solution kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Then, splenocytes were 
co-incubated with Colon26-GFP cells, which were irradiated with 100 Gy and incubated with 
INF-γ (100U/ml) (Wako Pure Chemical Industries, Osaka, Japan), for 5 days for stimulation. 
After CD8-positive selection by CD8 (TIL) MicroBeads (Miltenyi Biotec) and LS Columns 
(Miltenyi Biotec), Colon26-GFP cells (Target) were incubated with the CD8-positive cells 
(Effector) for 4 hours at 37°C at different ratios of Effector:Target (0:1, 10:1 and 20:1). After 
staining with Zombie NIR (Biolegend) to label dead cells, cells were analyzed with FACS 
Array (BD Biosciences). 
 
Statistical analysis 
Statistical analysis was performed using JMP software (SAS Institute, Cary, NC, USA). 
Student’s t test was used to assess the significance of differences in most continuous 
variables, except for quantitative immunohistochemical analyses of CD8, CD4, Foxp3, and 
CD11c and analyses of tumor growth in the orthotopic tumor model, for which the Wilcoxon 
signed-rank test was used. The log-rank test was used for Kaplan-Meier survival analyses. P 
values <0.05 were considered significant. 
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Figure Legends 
Figure 1. Cytotoxic activity of OBP-502 against murine gastrointestinal cancer cell lines 
(A) Viability of CT26 and PAN02 cells was assessed using an XTT assay 3 days after OBP-
502 treatment at the indicated doses (MOI). The percentage of viable cells relative to non-
treated cells (0 MOI) was plotted. Error bars indicate 95% confidence intervals. (B) Whole-
cell lysates of CT26 and PAN02 cells collected 3 days after OBP-502 treatment (0, 10, 100, 
500, and 1000 MOI) were subjected to Western blot analysis of E1A, PARP, p62, PD-L1, 
and β-Actin expression. Cleaved PARP (C-PARP) and p62 indicate induction of apoptosis 
and autophagy, respectively. (C) CT26 and PAN02 cells treated with OBP-502 (1000 MOI) 
were subjected to flow cytometry for analysis of PD-L1 expression on the cell surface 3 days 
after treatment. 
 
Figure 2. Active release of immunogenic molecules and chemokines by OBP-502 in vitro 
(A) Extracellular ATP secreted from CT26 and PAN02 cells was measured using a 
luminescence assay 24 h after OBP-502 treatment (0, 500, and 1000 MOI). *, P < 0.001. (B) 
Extracellular HMGB1 secreted from CT26 and PAN02 cells was measured using an ELISA 
24 h after OBP-502 treatment (0, 500, and 1000 MOI). *, P < 0.001. **, P < 0.005. (C) 
Cytokines and chemokines secreted from CT26 cells were measured using multi-cytokine 
and chemokine assays 24 h after OBP-502 treatment (0 and 1000 MOI), and ratio of 1000 
MOI to 0 MOI was plotted for each cytokine or chemokine. (D) CCL5/RANTES secreted 
from CT26 cells and PAN02 cells was measured using an ELISA 24 h after OBP-502 
treatment (0, 500, and 1000 MOI). *, P < 0.001. 
 
Figure 3. Recruitment of CD8-positive lymphocytes to tumors and development of 
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acquired antitumor immunity mediated by OBP-502 
(A) Study protocol. Briefly, CT26 or PAN02 subcutaneous tumors, intratumorally treated 
with OBP-502 (1×109 PFU) or PBS 3 times each week, were harvested at 7 days after 
initiation of treatment for immunohistochemical staining. (B) Representative figures of 
immunohistochemical staining for CD8, CD11c, CD4, and Foxp3 in CT26 tumor tissues. 
Scale bar, 100 µm. (C) Median number of TILs expressing CD8, CD11c, CD4, and Foxp3 
was statistically assessed from 5 selected fields. *, P < 0.05. **, P < 0.005. ***, P < 0.001. 
(D) Representative figures of FACS for CTL assay in which cytotoxicity of CD8-positive 
lymphocytes (Effector) harvested from the spleen of mice treated with OBP-502 (1×109 
PFU) or PBS on Colon26-GFP cells (Target) was analyzed at different ratios of 
Effector:Target of 0:1, 10:1 and 20:1. Cells in the area surrounded by the black border are 
dead Colon26-GFP cells. E:T stands for Effector:Target. (E) Percentage of dead cells in CTL 
assay was statistically assessed between PBS and OBP-502 (n=3). *, P < 0.05. (F) Protocol 
for the vaccination study. Briefly, CT26 or PAN02 cells treated with OBP-502 (1000 MOI) 
for 3 days were administered subcutaneously into the flank of BALB/c or C57/BL6 mice on 
day -7, -4, and -1 for vaccination, and CT26 or PAN02 cells (1×105 cells) were inoculated 
subcutaneously on day 0. (G) Tumor volume was monitored until day 28 and compared 
between PBS and vaccinated mice. *, P < 0.05. **, P < 0.005. (H) Representative figures of 
immunohistochemical staining for CD8-positive TILs in tumor tissues harvested 35 days 
after PAN02 inoculation in mice vaccinated with OBO-502–treated PAN02 cells or PBS. 
Scale bar, 100 µm. (I) Median number of TILs expressing CD8 was statistically assessed 
from 5 selected fields. *, P < 0.05. 
 
Figure 4. Antitumor effects of combination therapy in a subcutaneous tumor model 
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(A) Study protocol. Briefly, CT26 or PAN02 tumors were treated with OBP-502 (1×109 PFU) 
intratumorally and/or PD-1 Ab (1st: 20 mg/kg, 2nd and 3rd: 10 mg/kg) intraperitoneally 3 
times each week. (B) Volume of CT26 tumors was monitored until day 28 (n=12). Statistical 
analysis was performed on day 21. Right table shows the number of mice in which tumors 
were completely eradicated in each treatment group. *, P < 0.01. **, P < 0.0005. (C) Four 
tumor-free mice cured by combination therapy of OBP-502 and PD-1 Ab in the 
experiment shown in (B) were re-challenged with CT26 inoculation (5×105 cells). Four 
naïve mice were inoculated with CT26 cells (5×105 cells) and used as controls. Tumor 
volume was monitored until day 28. Right table shows the number of mice in which tumors 
did not develop in each group. **, P < 0.005. (D) Volume of PAN02 tumors was monitored 
until day 28 (n=7). Right table shows the number of mice in which tumors were completely 
eradicated in each treatment group. *, P < 0.01. (E) Representative figures for each treatment 
group of immunohistochemical staining for CD8-positive TILs in tumor tissues harvested 28 
days after initiation of treatment. Scale bar, 100 µm. 
 
Figure 5. Abscopal effects of combination therapy in a bilateral subcutaneous tumor 
model 
(A) Study protocol. Briefly, in the bilateral subcutaneous tumor model, one side was treated 
with OBP-502 intratumorally (1×109 PFU) 3 times each week, and the other side was left 
untreated with OBP-502. PD-1 Ab was administered intraperitoneally (1st: 20 mg/kg, 2nd 
and 3rd: 10 mg/kg) 3 times each week. (B) Volume of CT26 tumors treated with PBS or 
OBP-502 was monitored separately at the OBP-502-treated site and untreated site until day 
24 (n=7). *, P < 0.001. **, P < 0.05. (C) The same experiment shown in (B) was performed 
using BALB/c nude mice, and tumor volume was monitored until day 21 (n=7). (D) Volume 
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of CT26 tumors treated with PBS, monotherapy with OBP-502 or PD-1 Ab, or combination 
of both was monitored separately at the OBP-502-treated site and untreated site until day 24 
(n=6). *, P < 0.005. **, P < 0.05. (E) Representative figures for each treatment group of 
immunohistochemical staining for CD8-positive TILs in OBP-502-treated tumor tissues and 
untreated tumor tissues harvested 28 days after initiation of treatment. Scale bar, 100 µm. (F) 
Median number of CD8-positive TILs in OBP-502-treated tumor tissues and untreated 
tumor tissues was statistically assessed from 5 selected fields. *, P < 0.005. **, P < 0.001. 
***, P < 0.05. (G) Four mice rendered tumor free (OBP-502-treated site) by combination 
therapy with OBP-502 and PD-1 Ab in the experiment shown in (D) were re-challenged 
with CT26 inoculation (5×105 cells). Four naïve mice were inoculated with CT26 cells 
(5×105 cells) and used as controls. Tumor volume was monitored until day 28. *, P < 0.005. 
 
Figure 6. Antitumor effects of combination therapy in a CT26 orthotopic rectal tumor 
model with liver metastases 
(A) Study protocol. Briefly, in the CT26-Luc orthotopic rectal tumor model with liver 
metastases, CT26-Luc rectal tumors were treated with OBP-502 (1×109 PFU) intratumorally 
and PD-1 Ab (1st: 20 mg/kg, 2nd and 3rd: 10 mg/kg) intraperitoneally 3 times each week. (B) 
Kaplan-Meier survival analysis (n=8). *, P < 0.05. (C) Representative IVIS images of mice 
28 days after initiation of treatment with PBS, monotherapy with OBP-502 or PD-1 Ab, or 
combination of both. (D, E) Luminescence intensity of rectal tumors and liver metastases was 
measured using the IVIS imaging system on day 21 (n=8). *, P < 0.05. **, P < 0.001. (F, G) 
Macroscopic findings and H.E. staining of liver metastases harvested 14 days after initiation 
of treatment with PBS, monotherapy with OBP-502 or PD-1 Ab, or combination of both 
(twice, on days 0 and 7). Scale bar, 20 µm. 
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